Correlation between weight loss and improvement of diabetes mellitus among obese type 2 diabetic patients

Diabetology International

Volumn 4, Issue 2, 2013, Pages 132-137

  Harayama, Takuya ^a   Yoshida, Toshihide ^a   Yoshioka, Keiji ^b   Kogure, Akinori ^a   Sakai, Ryosuke ^a   Yasui, Tetsuya ^a   Kondo, Yuriko ^a   Fukui, Michiaki ^c   Hasegawa, Goji ^c   Nakamura, Naoto ^c  

^a KYOTO CITY HOSPITAL   (Japan)

^b Yoshioka Diabetes Clinic   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

75 g OGTT; Diet therapy; Obesity; Type 2 diabetes; Weight reduction

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

ADULT; ARTICLE; BODY WEIGHT; CORRELATION ANALYSIS; DIABETIC PATIENT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; WEIGHT REDUCTION;

EID: 84880446884     PISSN: 21901678     EISSN: 21901686     Source Type: Journal    
DOI: 10.1007/s13340-013-0107-1     Document Type: Article

References (21)

1. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab. 2000;2: 105-12.
2. Chow CC, Ko GT, Tsang LW, Yeung VT, Chan JC, Cockram CS. Dexfenfluramine in NIDDM patients. Diabetes Care. 1997;20: 1122-7.
3. Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M, Hanafusa T, Haneda M, Ueki K. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus: The Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Diabetol Int. 2010;1: 2-20.
4. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, Tominaga M, Oikawa S, Noda M, Kawamura T, Sanke T, Namba M, Hashiramoto M, Sasahara T, Nishio Y, Kuwa K, Ueki K, Takei I, Umemoto M, Murakami M, Yamakado M, Yatomi Y, Ohashi H. Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society (JDS): International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int. 2012;3: 8-10.
5. Harayama T, Kusunoki C, Ohse Y, Yoshida T. 8 cases whose diabetes mellitus could be normalized by a large quantity of weight loss. Foria Endocrinologica Japonica 2008;84: 273 (in Japanese).
6. Kusunoki C, Harayama T, Umekawa T, Yoshida T. Three obese cases of type 2 diabetes mellitus associated with metabolic syndrome, who could substantially lower their insulin requirement by losing body weight. J Japan Diab Soc. 2007;50: 247-54. (in Japanese, Abstract in English).
7. Smith DE, Heckemeyer T, Cuzuk M, Kratt PP, Mason DA. Motivational interviewing to improve adherence to a behavioral weight-control program for older obese women with NIDDM: a pilot study. Diabetes Care. 1997; 20: 52-4.
8. Yoshida T. The knack of obesity treatment for Japanese obese patients. Tokyo: Makino Publishing Co; 2008. (in Japanese).
9. Diabetes Prevention Program Research Groups. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformine. N Engl J Med. 2002; 346: 393-403.
10. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract. 2005;67: 152-62.
11. Sjöstrom L, Rissanen A, Andersen T, Bildrin M, Golay A, Koppeschaar HPF, Krempf M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998;352: 167-73.
12. Torgerson JS, Hauptman J, Boldrin MN, Sjöstrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care. 2004;27: 155-61.
13. Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, The STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet. 2002;359: 2072-7.
14. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord. 1992;16: 397-415.
15. Gokcel A, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB, Guvener N. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care. 2001;24: 1957-60.
16. Krejs GJ. Metabolic benefits associated with sibutramine therapy. Int J Obes Relat Metab Disord. 2002;26: S34-7.
17. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JB, Sledge I. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122: 248-56.
18. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 1993;259: 87-91.
19. Steppan CM, Balley ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature. 2001;409: 307-12.
20. Defronzo RA. Lilly Lecture 1987. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988;37: 667-687.
21. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diab Res Clin Prac. 2004;66: S37-43.